BridgeBio Pharma PE Ratio 2018-2024 | BBIO
Current and historical p/e ratio for BridgeBio Pharma (BBIO) from 2018 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. BridgeBio Pharma PE ratio as of November 01, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| BridgeBio Pharma PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-10-31 |
23.41 |
|
0.00 |
| 2024-06-30 |
25.33 |
$-2.63 |
0.00 |
| 2024-03-31 |
30.92 |
$-3.22 |
0.00 |
| 2023-12-31 |
40.37 |
$-3.94 |
0.00 |
| 2023-09-30 |
26.37 |
$-3.90 |
0.00 |
| 2023-06-30 |
17.20 |
$-3.75 |
0.00 |
| 2023-03-31 |
16.58 |
$-2.84 |
0.00 |
| 2022-12-31 |
7.62 |
$-3.27 |
0.00 |
| 2022-09-30 |
9.94 |
$-3.36 |
0.00 |
| 2022-06-30 |
9.08 |
$-3.49 |
0.00 |
| 2022-03-31 |
10.15 |
$-4.08 |
0.00 |
| 2021-12-31 |
16.68 |
$-3.91 |
0.00 |
| 2021-09-30 |
46.87 |
$-3.91 |
0.00 |
| 2021-06-30 |
60.96 |
$-3.83 |
0.00 |
| 2021-03-31 |
61.60 |
$-4.20 |
0.00 |
| 2020-12-31 |
71.11 |
$-3.80 |
0.00 |
| 2020-09-30 |
37.52 |
$-3.41 |
0.00 |
| 2020-06-30 |
32.61 |
$-2.43 |
0.00 |
| 2020-03-31 |
29.00 |
$-1.91 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
